UK – 2 March 2022 – Tetris Pharma has finalised an exclusive supply and distribution agreement with Primex Pharmaceuticals for a flavoured oral solution of midazolam licenced for paediatric use >6 months of age. Tetris Pharma and Primex Pharmaceuticals announced this strategic agreement yesterday (01/03/22) to further commercialise the product in the UK. The new agreement further strengthens Tetris Pharma’s position within the UK as it continues to embark on extending the platform across Europe.
Dr Shafiq Choudhary, CEO of Tetris Pharma, commented:
“We are very excited to be working with Primex Pharmaceuticals. This strengthens our position as a specialty pharmaceutical company in the UK as we look to grow and further develop our pipeline. Working alongside Primex is an exciting milestone for Tetris Pharma.”
Alan Knox, CEO of Primex Pharmaceuticals. commented:
“Primex Pharmaceuticals is delighted to have Tetris Pharma as their strategic partner in the UK to continue the commercialisation of our flavoured oral solution of Midazolam which is now available in over 9 countries in the EU.”